Ibruxen-140mg-Ibrutinib - Imbruvica - Meds For Cancer

News Discuss 
Ibrutinib(Ibruxen 140mg), a BTK inhibitor, has shown promising results when combined with venetoclax, an anti-BCL-2 inhibitor, for treating chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). While ibrutinib alone can induce responses in 68% of patients. https://medsforcancer.com/product/ibruxen-140mg-ibrutinib/


    No HTML

    HTML is disabled

Who Upvoted this Story